Showing 1111-1120 of 1281 results for "".
- Neuro-Optometric Rehabilitation Association Appoints Barbara Barclay as New Executive Directorhttps://modernod.com/news/neuro-optometric-rehabilitation-association-appoints-barbara-barclay-as-new-executive-director/2482455/The Neuro-Optometric Rehabilitation Association, International (NORA), has announced the appointment of Barbara Barclay as its new executive director, effective October 1. Ms. Barclay, an expert in eye-tracking technology and health tech, brings more than 30 years of leadership experience, i
- Abigail Markward Named Executive Director of ASOAhttps://modernod.com/news/abigail-markward-named-executive-director-of-asoa/2482399/The American Society of Ophthalmic Administrators (ASOA) has announced the appointment of Abigail Markward, MBA, as its new executive director, effective immediately. In addition to this new role, Ms. Markward will continue her responsibilities as executive director of the ASCRS Foundation, a pos
- Karen Petrou Appointed Board Chair of the Foundation Fighting Blindnesshttps://modernod.com/news/karen-petrou-appointed-board-chair-of-the-foundation-fighting-blindness/2482334/The Foundation Fighting Blindness announced the appointment of Karen Petrou as Board Chair, effective July 1, 2024. Petrou succeeds David Brint, who is retiring after 8 years of service. Ms. Petrou’s becomes the third person to hold the position in the Foundation&rs
- Lucentis Biosimilar Receives Marketing Authorization from the Saudi Food & Drug Authorityhttps://modernod.com/news/lucentis-biosimilar-receives-marketing-authorization-from-the-saudi-food-drug-authority/2482156/Formycon AG and MS Pharma announced that Ravegza (FYB201), a biosimilar to Lucentis (ranibizumab), has received marketing authorization from the Saudi Food & Drug Authority. Ravegza is approved in Saudi Arabia for the treatment of patients with wet age-related macular
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- Ashley Magargee Named CEO of Genentechhttps://modernod.com/news/genentech-names-ashley-magargee-as-ceo/2482008/Ashley Magargee has been appointed Chief Executive Officer (CEO) of Genentech, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Ms. Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will repo
- ASCRS Names Abigail Markward New Executive Directorhttps://modernod.com/news/ascrs-names-abigail-markward-new-executive-director/2481952/The American Society of Cataract and Refractive Surgery (ASCRS) has named Abigail Markward as the new Executive Director of the ASCRS Foundation. Ms. Markward has more than two decades of expertise in strategic communications, marketing, publishing, and nonprofit roles. Most recent
- Erin Powers Joins J&J Vision as Vice President of US Sales and Marketing for its Surgical Vision Portfoliohttps://modernod.com/news/erin-powers-joins-jj-vision-as-vice-president-of-us-sales-and-marketing-for-its-surgical-vision-portfolio/2481838/Johnson & Johnson announced the appointment of Erin Powers to the position of Vice President of US Sales and Marketing for its Surgical Vision portfolio. Ms. Powers will lead the US sales, marketing, and professional education teams, and will join the company within t
- Oculis Appoints Rebecca Weil, PhD, as Chief Commercial Officer as it Enters Pre-Commercial Phasehttps://modernod.com/news/oculis-appoints-rebecca-weil-phd-as-chief-commercial-officer-as-it-enters-pre-commercial-phase/2481823/Oculis announced the appointment of Rebecca Weil, PhD, to the role of Chief Commercial Officer. In this role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for US and globally, and building the required commercial infrastructure to bring all of
- CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operationshttps://modernod.com/news/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations/2481468/CXL Ophthalmics announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations. With more than 25 years of experience in ophthalmology, Ms. Haynes previously served as Global Director, Medical Affairs for Johnson & Johnson Vision. There, she was respo